uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Analysts

uniQure N.V. (NASDAQ:QURE) has been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $37.82.

Several research analysts have recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of uniQure in a research note on Friday, May 30th. Finally, Cantor Fitzgerald raised uniQure to a “strong-buy” rating in a research note on Monday, May 19th.

uniQure Stock Down 0.8%

NASDAQ QURE opened at $14.31 on Thursday. The stock’s 50-day moving average price is $14.54 and its 200-day moving average price is $13.93. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53. uniQure has a 52 week low of $3.76 and a 52 week high of $19.18. The company has a market capitalization of $783.90 million, a P/E ratio of -3.26 and a beta of 0.08.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.25. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. On average, equities research analysts predict that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling at uniQure

In other news, Director Madhavan Balachandran sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director owned 37,697 shares in the company, valued at approximately $544,721.65. The trade was a 5.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director owned 34,190 shares of the company’s stock, valued at approximately $494,045.50. This trade represents a 5.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock worth $322,426 over the last three months. 4.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Large investors have recently bought and sold shares of the business. Twin Tree Management LP purchased a new position in uniQure during the 4th quarter valued at $77,000. ADAR1 Capital Management LLC bought a new stake in uniQure during the 4th quarter valued at $177,000. Mraz Amerine & Associates Inc. bought a new stake in uniQure during the 1st quarter valued at $106,000. Wells Fargo & Company MN raised its position in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 1,503 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in uniQure during the 1st quarter valued at $152,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.